Protocol Ledger

NCT05179876 · Phase III · RECRUITING

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Interventional Phase III clinical trial protocol NCT05179876 sponsored by Johnson & Johnson / Janssen in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-04 Enrollment: 280 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05179876
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)280 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05179876
Protocol FieldVerified Registry Value
NCT IdentifierNCT05179876
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment280 participants (ESTIMATED)
Registered Start Date2022-05-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05179876
Hospital Research SiteLocationSite Profile
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Jiangsu Province HospitalNanjing, ChinaOpen Hospital Dossier ->
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->
Gachon University Gil Medical CenterIncheon, South KoreaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI